ACURX PHARMACEUTICALS, LLC
259 Liberty Avenue
Staten Island, NY 10305
June 22, 2021
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Jane Park
Re: | Acurx Pharmaceuticals, LLC | ||
Registration Statement on Form S-1 | |||
File No. 333-256516 | |||
Request for Acceleration |
Dear Ms. Park:
Pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, Acurx Pharmaceuticals, LLC (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-256516), so that it may become effective at 5:00 p.m. (Washington, D.C. time) on Thursday, June 24, 2021, or as soon thereafter as practicable.
Please call Ivan Blumenthal, of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, at (212) 692-6784 with any comments or questions regarding this matter.
Very truly yours, Acurx Pharmaceuticals, LLC | ||||
By: | /s/ David Luci | |||
Name: | David Luci | |||
Title: | President and Chief Executive Officer | |||
cc: | Acurx Pharmaceuticals, LLC |
David Luci
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Ivan K. Blumenthal, Esq.
|